Elevar Therapeutics
Saeho Chong has a diverse work experience spanning several prestigious organizations. Saeho is currently the Chief Executive Officer at Elevar Therapeutics since March 2022. Prior to this, they held various roles at Alnylam Pharmaceuticals from 2017 to 2022, including Vice President of DMPK and Bioanalysis and Senior Director of DMPK. In 2016, they worked as a Clinical Pharmacologist at the FDA. From 2012 to 2014, Saeho served as a Director at Takeda Pharmaceuticals. Before that, they were a Professor at Seoul National University from 2009 to 2012. Saeho began their career at Bristol-Myers Squibb in 1990, where they worked as a DMPK professional until 2009.
Saeho Chong has pursued a Doctor of Philosophy (Ph.D.) degree in Pharmaceutics from the University at Buffalo. No specific information about the start or end years of their education is available at this time.
This person is not in any offices
Elevar Therapeutics
Elevar Therapeutics is a pharmaceutical company that specializes in the development of therapies for unmet medical needs in cancer. The company is developing two proprietary drug candidates; rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a BTK/JAK3 inhibitor with thepotential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent.Elevar Therapeutics holds worldwide rights for rivoceranib excluding China and has partnered for development and marketing in South Korea.